A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: A pilot study in Taiwan

Liver International

Volumn 26, Issue 1, 2006, Pages 73-81

  Yu, Ming Lung ^a,b   Dai, Chia Yen ^a,b,c   Lin, Z Y Zu Yau ^a,b   Lee, Li Po ^b   Hou, Nei Jen ^c   Hsieh, Ming Yen ^b   Chen, Shinn Cherng ^a,b   Hsieh, Ming Yuh ^a,b   Wang, Liang Yen ^a,b   Chang, Wen Yu ^a,b   Chuang, Wan Long ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Duration; Fibrosis; HCV; PEG interferon; Ribavirin; Viral load

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; CHILL; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INJECTION SITE ERYTHEMA; INSOMNIA; LEUKOPENIA; LIVER FIBROSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN MANIFESTATION; TAIWAN; THROMBOCYTOPENIA; THYROID DISEASE; VIRUS LOAD; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PILOT PROJECTS; PROBABILITY; REFERENCE VALUES; RIBAVIRIN; RISK ASSESSMENT; ROC CURVE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TAIWAN; TREATMENT OUTCOME;

EID: 33645998724     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01196.x     Document Type: Article

References (29)

1. Lai M Y, Kao J H, Yang P M, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.
2. Mchutchison J G, Gordon S C, Schiff E R, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
3. Poynard T, Marcellin P, Lee S S, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
4. Pawlotsky J M, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654-659.
5. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999; 31 (Suppl. 1): 3-8.
6. Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
7. Manns M P, Mchutchison J G, Gordon S C, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
8. Hadziyannis S J, Sette H Jr, Morgan T R, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
9. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1-46.
10. Chuang W L, Yu M L, Dai C Y, Chang W Y. Treatment of chronic hepatitis C in Southern Taiwan. Intervirology 2005, 49: 99-106.
11. Lee S D, Yu M L, Cheng P N, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12: 283-91.
12. Lauer G M, Walker B D. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
13. Yu M L, Chuang W L, Dai C Y, et al. Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test. J Clin Microbiol 2000; 38: 2933-9.
14. Yu M L, Dai C Y, Chen S C, et al. A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. Antiviral Res 2004; 63: 25-32.
15. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74 (Part 11): 2385-90.
16. Knodell R G, Ishak K G, Black W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
17. Jeffers L J, Cassidy W, Howell C D, Hu S, Reddy K R. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-8.
18. Muir A J, Bornstein J D, Killenberg P G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-71.
19. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-30.
20. Hung C H, Lee C M, Lu S N, et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003; 10: 87-94.
21. Cappiello G, Abbate I, Lo Iacono O, et al. ISDR pattern and evolution in patients with chronic hepatitis C treated with standard or PEG-IFN plus ribavirin. Antivir Ther 2003; 8: 105-10.
22. Pascu M, Martus P, Hohne M, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: A meta-analysis focused on geographical differences. Gut 2004; 53: 1345-51.
23. Thio C L, Thomas D L, Goedert J J, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184: 16-21.
24. Yu M L, Dai C Y, Chen S C, et al. Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection. J Infect Dis 2003; 188: 62-5.
25. Davis G L, Wong J B, Mchutchison J G, Manns M P, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
26. Heathcote E J. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004; 127: S294-302.
27. Lee W M, Dienstag J L, Lindsay K L, et al. Evolution of the HALT-C Trial: Pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472-92.
28. Drusano G L, Preston S L. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964-70.
29. Mchutchison J G, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.